Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue.
GSK-3β
Parkinson’s disease
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
17 Feb 2024
17 Feb 2024
Historique:
received:
24
09
2023
accepted:
20
01
2024
medline:
17
2
2024
pubmed:
17
2
2024
entrez:
17
2
2024
Statut:
aheadofprint
Résumé
Parkinson's disease (PD) is a progressive neurodegenerative disease of the brain due to degeneration of dopaminergic neurons in the substantia nigra (SN). Glycogen synthase kinase 3 beta (GSK-3β) is implicated in the pathogenesis of PD. Therefore, the purpose of the present review was to revise the mechanistic role of GSK-3β in PD neuropathology, and how GSK-3β inhibitors affect PD neuropathology. GSK-3 is a conserved threonine/serine kinase protein that is intricate in the regulation of cellular anabolic and catabolic pathways by modulating glycogen synthase. Over-expression of GSK-3β is also interconnected with the development of different neurodegenerative diseases. However, the underlying mechanism of GSK-3β in PD neuropathology is not fully clarified. Over-expression of GSK-3β induces the development of PD by triggering mitochondrial dysfunction and oxidative stress in the dopaminergic neurons of the SN. NF-κB and NLRP3 inflammasome are activated in response to dysregulated GSK-3β in PD leading to progressive neuronal injury. Higher expression of GSK-3β in the early stages of PD neuropathology might contribute to the reduction of neuroprotective brain-derived neurotrophic factor (BDNF). Thus, GSK-3β inhibitors may be effective in PD by reducing inflammatory and oxidative stress disorders which are associated with degeneration of dopaminergic in the SN.
Identifiants
pubmed: 38367137
doi: 10.1007/s12035-024-04003-z
pii: 10.1007/s12035-024-04003-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Ahmed EA, Batiha GES (2023) SARS-COV-2 infection and Parkinson’s disease: possible links and perspectives. J Neurosci Res 101(6):952–975
pubmed: 36717481
doi: 10.1002/jnr.25171
Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK (2023) The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways. Ageing Res Rev 91:102075. https://doi.org/10.1016/j.arr.2023.102075
doi: 10.1016/j.arr.2023.102075
pubmed: 37714384
Heras-Garvin A, Stefanova N (2020) From synaptic protein to prion: the long and controversial journey of α-synuclein. Front Synaptic Neurosci 12:584536
pubmed: 33071772
pmcid: 7536368
doi: 10.3389/fnsyn.2020.584536
Alrouji M, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Jabir MS et al (2023) NF-κB/NLRP3 inflammasome axis and risk of Parkinson’s disease in type 2 diabetes mellitus: a narrative review and new perspective. J Cell Mol Med 27(13):1775–1789. https://doi.org/10.1111/jcmm.17784
doi: 10.1111/jcmm.17784
pubmed: 37210624
pmcid: 10315781
Xu B, Fan F, Liu Y, Liu Y, Zhou L, Yu H (2023) Distinct effects of familial Parkinson’s disease-associated mutations on α-synuclein phase separation and amyloid aggregation. Biomolecules 13(5):726
pubmed: 37238596
pmcid: 10216457
doi: 10.3390/biom13050726
Airavaara M, Parkkinen I, Konovalova J, Albert K, Chmielarz P, Domanskyi A (2020) Back and to the future: from neurotoxin-induced to human Parkinson’s disease models. Curr Protoc Neurosci 91(1):e88
pubmed: 32049438
doi: 10.1002/cpns.88
Chung SJ, Yoo HS, Lee YH, Lee PH, Sohn YH (2019) Heterogeneous patterns of striatal dopamine loss in patients with young-versus old-onset Parkinson’s disease: impact on clinical features. J Mov Disord 12(2):113
pubmed: 31158944
pmcid: 6547040
doi: 10.14802/jmd.18064
Consonni A, Miglietti M, De Luca CMG, Cazzaniga FA, Ciullini A, Dellarole IL et al (2022) Approaching the gut and nasal microbiota in Parkinson’s disease in the era of the seed amplification assays. Brain Sci 12(11):1579
pubmed: 36421902
pmcid: 9688507
doi: 10.3390/brainsci12111579
Hou X, Watzlawik JO, Fiesel FC, Springer W (2020) Autophagy in Parkinson’s disease. J Mol Biol 432(8):2651–2672
pubmed: 32061929
pmcid: 7211126
doi: 10.1016/j.jmb.2020.01.037
Li K-L, Huang H-Y, Ren H, Yang X-L (2022) Role of exosomes in the pathogenesis of inflammation in Parkinson’s disease. Neural Regen Res 17(9):1898–1906. https://doi.org/10.4103/1673-5374.335143
doi: 10.4103/1673-5374.335143
pubmed: 35142665
pmcid: 8848593
Kung H-C, Lin K-J, Kung C-T, Lin T-K (2021) Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson’s disease. Biomedicines 9(8):918
pubmed: 34440122
pmcid: 8389563
doi: 10.3390/biomedicines9080918
Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z et al (2015) Glycogen synthase kinase-3 beta (GSK-3β) signaling: implications for Parkinson’s disease. Pharmacol Res 97:16–26
pubmed: 25829335
doi: 10.1016/j.phrs.2015.03.010
Kaidanovich-Beilin O, Woodgett JR (2011) GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 4:40
pubmed: 22110425
pmcid: 3217193
doi: 10.3389/fnmol.2011.00040
Manduca JD, Thériault R-K, Perreault ML (2020) Glycogen synthase kinase-3: the missing link to aberrant circuit function in disorders of cognitive dysfunction? Pharmacol Res 157:104819
pubmed: 32305493
doi: 10.1016/j.phrs.2020.104819
Noori T, Dehpour AR, Sureda A, Fakhri S, Sobarzo-Sanchez E, Farzaei MH et al (2020) The role of glycogen synthase kinase 3 beta in multiple sclerosis. Biomed Pharmacother 132:110874
pubmed: 33080467
doi: 10.1016/j.biopha.2020.110874
Lee YH, Choi H-J, Kim JY, Kim J-E, Lee J-H, Cho S-H et al (2021) Ginsenoside Rg4 enhances the inductive effects of human dermal papilla spheres on hair growth via the AKT/GSK-3β/β-catenin signaling pathway. J Microbiol Biotechnol 31(7):933
pubmed: 34099599
pmcid: 9706015
doi: 10.4014/jmb.2101.01032
Jianing L, Shiqun S, Jia L, Xuetao Z, Zehua L, Tong S et al (2021) NCAPG, mediated by miR-378a-3p, regulates cell proliferation, cell cycle progression, and apoptosis of oral squamous cell carcinoma through the GSK-3β/β-catenin signaling. Neoplasma 68(6):1201–1211. https://doi.org/10.4149/neo_2021_210421N544
doi: 10.4149/neo_2021_210421N544
Feng J, Xie L, Yu X, Liu C, Dong H, Lu W et al (2021) Perilipin 5 ameliorates high-glucose-induced podocyte injury via Akt/GSK-3β/Nrf2-mediated suppression of apoptosis, oxidative stress, and inflammation. Biochem Biophys Res Commun 544:22–30
pubmed: 33516878
doi: 10.1016/j.bbrc.2021.01.069
Llorens-Marítin M, Jurado J, Hernández F, Ávila J (2014) GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 7:46
pmcid: 4033045
Ahn M, Kim J, Park C, Cho J, Jee Y, Jung K et al (2017) Potential involvement of glycogen synthase kinase (GSK)-3β in a rat model of multiple sclerosis: evidenced by lithium treatment. Anat Cell Biol 50(1):48–59
pubmed: 28417055
pmcid: 5386926
doi: 10.5115/acb.2017.50.1.48
Ting H-C, Yang H-I, Harn H-J, Chiu I-M, Su H-L, Li X et al (2021) Coactivation of GSK3β and IGF-1 attenuates amyotrophic lateral sclerosis nerve fiber cytopathies in SOD1 mutant patient-derived motor neurons. Cells 10(10):2773
pubmed: 34685754
pmcid: 8535155
doi: 10.3390/cells10102773
Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier J-M et al (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290
pubmed: 36291224
pmcid: 9599431
doi: 10.3390/brainsci12101290
Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S (2023) Benzodiazepines in Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacology 31(1):221–230
pubmed: 36418599
doi: 10.1007/s10787-022-01099-4
Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33(1):43–55
pubmed: 17239007
doi: 10.1111/j.1365-2990.2006.00795.x
Zhang Y, Huang N-Q, Yan F, Jin H, Zhou S-Y, Shi J-S et al (2018) Diabetes mellitus and Alzheimer’s disease: GSK-3β as a potential link. Behav Brain Res 339:57–65
pubmed: 29158110
doi: 10.1016/j.bbr.2017.11.015
Yang Y, Wang L, Zhang C, Guo Y, Li J, Wu C et al (2022) Ginsenoside Rg1 improves Alzheimer’s disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK-3β/β-catenin signaling pathway. Chem Biol Drug Des 99(6):884–896
pubmed: 35313087
doi: 10.1111/cbdd.14041
Zhang H, Wang X, Xu P, Ji X, Chi T, Liu P et al (2020) Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer’s disease models. J Physiol Sci 70:1–11
doi: 10.1186/s12576-020-00757-y
Koh S-H, Baek W, Kim SH (2011) Brief review of the role of glycogen synthase kinase-3β in amyotrophic lateral sclerosis. Neurol Res Int 2011:205761. https://doi.org/10.1155/2011/205761
doi: 10.1155/2011/205761
pubmed: 21603026
pmcid: 3096311
Hu JH, Zhang H, Wagey R, Krieger C, Pelech S (2003) Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem 85(2):432–442
pubmed: 12675919
doi: 10.1046/j.1471-4159.2003.01670.x
Yang W, Leystra-Lantz C, Strong MJ (2008) Upregulation of GSK3β expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Res 1196:131–139
pubmed: 18221734
doi: 10.1016/j.brainres.2007.12.031
Tolosa L, Mir M, Olmos G, Llado J (2009) Vascular endothelial growth factor protects motoneurons from serum deprivation-induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition. Neuroscience 158(4):1348–1355
pubmed: 19041930
doi: 10.1016/j.neuroscience.2008.10.060
Klingl YE, Pakravan D, Van Den Bosch L (2021) Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. Br J Pharmacol 178(6):1353–1372
pubmed: 32726472
doi: 10.1111/bph.15217
Alruwaili M, Al-Kuraishy HM, Alexiou A, Papadakis M, ALRashdi BM, Elhussieny O et al (2023) Pathogenic role of fibrinogen in the neuropathology of multiple sclerosis: a tale of sorrows and fears. Neurochem Res 48(11):3255–69
pubmed: 37442896
pmcid: 10514123
doi: 10.1007/s11064-023-03981-1
Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Saad HM, Batiha GE-S, Klionsky DJ (2023) The beneficial role of autophagy in multiple sclerosis: yes or no? Autophagy 31(4):435–44. https://doi.org/10.1007/s12264-015-1545-5
doi: 10.1007/s12264-015-1545-5
Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S (2023) The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects. Inflammopharmacology 31(4):1671–1682. https://doi.org/10.1007/s10787-023-01240-x
doi: 10.1007/s10787-023-01240-x
pubmed: 37160526
Booth D, Arthur A, Teutsch S, Bye C, Rubio J, Armati P et al (2005) Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J Mol Med 83:822–830
pubmed: 16075257
doi: 10.1007/s00109-005-0684-y
Ko R, Lee SY (2016) Glycogen synthase kinase 3β in Toll-like receptor signaling. BMB Rep 49(6):305
pubmed: 26996345
pmcid: 5070717
doi: 10.5483/BMBRep.2016.49.6.059
Ghosouri S, Soleimani M, Bakhtiari M, Ghasemi N (2023) Evaluation of in vivo lithium chloride effects as a GSK3-β inhibitor on human adipose derived stem cells differentiation into oligodendrocytes and re-myelination in an animal model of multiple sclerosis. Mol Biol Rep 50(2):1617–1625
pubmed: 36526850
doi: 10.1007/s11033-022-08181-8
Pashaei S, Mohammadi P, Yarani R, Haghgoo SM, Aleagha MSE (2021) Carbohydrate and lipid metabolism in multiple sclerosis: clinical implications for etiology, pathogenesis, diagnosis, prognosis, and therapy. Arch Biochem Biophys 712:109030
pubmed: 34517010
doi: 10.1016/j.abb.2021.109030
Gong L, Zhang QL, Zhang N, Hua WY, Huang YX, Di PW et al (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson’s disease: linking to Akt/GSK 3β signaling pathway. J Neurochem 123(5):876–885
pubmed: 23094836
doi: 10.1111/jnc.12038
Singh S, Mishra A, Bharti S, Tiwari V, Singh J, Parul et al (2018) Glycogen synthase kinase-3β regulates equilibrium between neurogenesis and gliogenesis in rat model of Parkinson’s disease: a crosstalk with Wnt and notch signaling. Mol Neurobiol 55:6500–6517
pubmed: 29327199
doi: 10.1007/s12035-017-0860-4
Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu X et al (2007) Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52(8):1678–1684
pubmed: 17517424
doi: 10.1016/j.neuropharm.2007.03.017
Khan SS, Janrao S, Srivastava S, Singh SB, Vora L, Khatri DK (2023) GSK-3β: an exuberating neuroinflammatory mediator in Parkinson’s disease. Biochem Pharmacol 210:115496. https://doi.org/10.1016/j.bcp.2023
doi: 10.1016/j.bcp.2023
Cao Q, Karthikeyan A, Dheen ST, Kaur C, Ling E-A (2017) Production of proinflammatory mediators in activated microglia is synergistically regulated by Notch-1, glycogen synthase kinase (GSK-3β) and NF-κB/p65 signalling. PLoS ONE 12(10):e0186764
pubmed: 29049420
pmcid: 5648239
doi: 10.1371/journal.pone.0186764
Lei P, Ayton S, Bush AI, Adlard PA (2011) GSK-3 in neurodegenerative diseases. Int J Alzheimer’s Dis 2011:189246. https://doi.org/10.4061/2011/189246
doi: 10.4061/2011/189246
Li J, Ma S, Chen J, Hu K, Li Y, Zhang Z et al (2020) GSK-3β contributes to parkinsonian dopaminergic neuron death: evidence from conditional knockout mice and tideglusib. Front Mol Neurosci 13:81
pubmed: 32581704
pmcid: 7283909
doi: 10.3389/fnmol.2020.00081
Eriksson I (2022) Dealing with damaged lysosomes: impact of lysosomal membrane stability in health and disease: Linköping University Electronic Press
Choi H-J, Cha SJ, Lee J-W, Kim H-J, Kim K (2020) Recent advances on the role of gsk3β in the pathogenesis of amyotrophic lateral sclerosis. Brain Sci 10(10):675
pubmed: 32993098
pmcid: 7600609
doi: 10.3390/brainsci10100675
Barr JL, Unterwald EM (2020) Glycogen synthase kinase-3 signaling in cellular and behavioral responses to psychostimulant drugs. Biochim et Biophys Acta (BBA)-Mol Cell Res 1867(9):118746
Yang L, Zhang X, Li S, Wang H, Zhang X, Liu L et al (2020) Intranasal insulin ameliorates cognitive impairment in a rat model of Parkinson’s disease through Akt/GSK3β signaling pathway. Life Sci 259:118159
pubmed: 32763288
doi: 10.1016/j.lfs.2020.118159
Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K et al (2011) Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β. FEBS J 278(24):4895–4904
pubmed: 21985244
doi: 10.1111/j.1742-4658.2011.08389.x
Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol 225(1):210–218
pubmed: 20599975
pmcid: 2922478
doi: 10.1016/j.expneurol.2010.06.017
Duka T, Duka V, Joyce JN, Sidhu A (2009) α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J 23(9):2820
pubmed: 19369384
pmcid: 2796901
doi: 10.1096/fj.08-120410
Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD et al (2005) GSK3B polymorphisms alter transcription and splicing in Parkinson’s disease. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 58(6):829–839
doi: 10.1002/ana.20691
Takaichi Y, Chambers JK, Ano Y, Takashima A, Nakayama H, Uchida K (2021) Deposition of phosphorylated α-synuclein and activation of GSK-3β and PP2A in the PS19 mouse model of tauopathy. J Neuropathol Exp Neurol 80(8):731–740
pubmed: 34151989
doi: 10.1093/jnen/nlab054
Van Kampen JM, Baranowski D, Kay DG (2014) Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson’s disease. PLoS ONE 9(5):e97032
pubmed: 24804730
pmcid: 4013129
doi: 10.1371/journal.pone.0097032
Gao X, Joselin AP, Wang L, Kar A, Ray P, Bateman A et al (2010) Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3β. Protein Cell 1:552–562
pubmed: 21204008
pmcid: 4875315
doi: 10.1007/s13238-010-0067-1
Soni D, Kumar P (2022) GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders. Pharmacol Rep 74(4):557–569
pubmed: 35882765
doi: 10.1007/s43440-022-00390-z
Di Martino RMC, Pruccoli L, Bisi A, Gobbi S, Rampa A, Martinez A et al (2020) Novel curcumin-diethyl fumarate hybrid as a dualistic GSK-3β inhibitor/Nrf2 inducer for the treatment of Parkinson’s disease. ACS Chem Neurosci 11(17):2728–2740
pubmed: 32663009
doi: 10.1021/acschemneuro.0c00363
Al-Kuraishy HM, Al-Kuraishi AH, Al-Windy S, Al-Gareeb AI (2019) Toxoplasmosis and risk of endothelial dysfunction: role of oxidative stress and pro-inflammatory mediators. Arch Clin Infect Dis 14(6). https://doi.org/10.5812/archcid.95563
Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ (2018) Concept and connotation of oxidative stress in preeclampsia. J Lab Phys 10(03):276–282
Al-Hussaniy HA, Al-Kuraishy HM, Abdulameer A-GA (2022) The use of Panax ginseng to reduce the cardiotoxicity of doxorubicin and study its effect on modulating oxidative stress, inflammatory, and apoptosis pathways. Open Access Maced J Med Sci 10(A):715–9
doi: 10.3889/oamjms.2022.9479
Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Aljowaie RM, Almutairi SM, Alexiou A et al (2022) The prospective effect of allopurinol on the oxidative stress index and endothelial dysfunction in Covid-19. Inflammation 45(4):1651–1667
pubmed: 35199285
doi: 10.1007/s10753-022-01648-7
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson’s disease. Front Neuroanat 9:91
pubmed: 26217195
pmcid: 4495335
doi: 10.3389/fnana.2015.00091
Ali NH, Alhamdan NA, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E, Batiha GE-S (2023) Irisin/PGC-1α/FNDC5 pathway in Parkinson’s disease: truth under the throes. Naunyn-Schmiedeberg’s Arch Pharmacol 1–11. https://doi.org/10.1007/s00210-023-02726-9
Gal S, Zheng H, Fridkin M, Youdim MB (2010) Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 17:15–27
pubmed: 19609632
doi: 10.1007/s12640-009-9070-9
Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK, Albukhaty S, Sulaiman GM et al (2023) Evaluation and targeting of amyloid precursor protein (APP)/amyloid beta (Aβ) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel. Ageing Res Rev 92:102119. https://doi.org/10.1016/j.arr.2023.102119
doi: 10.1016/j.arr.2023.102119
pubmed: 37931848
Blesa J, Przedborski S (2014) Parkinson’s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat 8:155
pubmed: 25565980
pmcid: 4266040
doi: 10.3389/fnana.2014.00155
Khan Z, Ali SA (2018) Oxidative stress-related biomarkers in Parkinson’s disease: a systematic review and meta-analysis. Iran J Neurol 17(3):137
pubmed: 30886681
pmcid: 6420691
Rojo AI, de Sagarra MR, Cuadrado A (2008) GSK-3β down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105(1):192–202
pubmed: 18005231
doi: 10.1111/j.1471-4159.2007.05124.x
Liu B, Zhang H, Tan X, Yang D, Lv Z, Jiang H et al (2017) GSPE reduces lead-induced oxidative stress by activating the Nrf2 pathway and suppressing miR153 and GSK-3β in rat kidney. Oncotarget 8(26):42226
pubmed: 28178683
pmcid: 5522062
doi: 10.18632/oncotarget.15033
Duarte AI, Santos P, Oliveira CR, Santos MS, Rego AC (2008) Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3β signaling pathways and changes in protein expression. Biochim et Biophys Acta (BBA)-Mol Cell Res 1783(6):994–1002
Wang D, Yang Y, Zou X, Zheng Z, Zhang J (2020) Curcumin ameliorates CKD-induced mitochondrial dysfunction and oxidative stress through inhibiting GSK-3β activity. J Nutr Biochem 83:108404
pubmed: 32531667
doi: 10.1016/j.jnutbio.2020.108404
Al-Kuraishy HM, Al-Gareeb AI, Fageyinbo MS, Batiha GE-S (2022) Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19. Futur Sci OA 8(5):FSO797. https://doi.org/10.2144/fsoa-2021-0099
Dolatshahi M, Ranjbar Hameghavandi MH, Sabahi M, Rostamkhani S (2021) Nuclear factor-kappa B (NF-κB) in pathophysiology of Parkinson disease: diverse patterns and mechanisms contributing to neurodegeneration. Eur J Neurosci 54(1):4101–4123
doi: 10.1111/ejn.15242
Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K et al (2004) Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J Biol Chem 279(48):49571–49574
pubmed: 15465828
doi: 10.1074/jbc.C400442200
Chen H, Yang S, Yang Z, Ma L, Jiang D, Mao J et al (2007) Inhibition of GSK-3β decreases NF-κB-dependent gene expression and impairs the rat liver regeneration. J Cell Biochem 102(5):1281–1289
pubmed: 17427960
doi: 10.1002/jcb.21358
Batiha GE-S, Al-Gareeb AI, Rotimi D, Adeyemi OS, Al-Kuraishy HM (2022) Common NLRP3 inflammasome inhibitors and Covid-19: divide and conquer. Sci Afr 18:e01407
pubmed: 36310607
pmcid: 9595499
de Araújo FM, Cuenca-Bermejo L, Fernandez-Villalba E, Costa SL, Silva VDA, Herrero MT (2022) Role of microgliosis and NLRP3 inflammasome in Parkinson’s disease pathogenesis and therapy. Cell Mol Neurobiol 42(5):1283–1300
pubmed: 33387119
doi: 10.1007/s10571-020-01027-6
Wang S, Yuan Y-H, Chen N-H, Wang H-B (2019) The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. Int Immunopharmacol 67:458–464
pubmed: 30594776
doi: 10.1016/j.intimp.2018.12.019
Fan Z, Pan Y-T, Zhang Z-Y, Yang H, Yu S-Y, Zheng Y et al (2020) Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease. J Neuroinflammation 17(1):1–10
doi: 10.1186/s12974-019-1670-6
Wang S-H, Cui L-G, Su X-L, Komal S, Ni R-C, Zang M-X et al (2022) GSK-3β-mediated activation of NLRP3 inflammasome leads to pyroptosis and apoptosis of rat cardiomyocytes and fibroblasts. Eur J Pharmacol 920:174830
pubmed: 35182545
doi: 10.1016/j.ejphar.2022.174830
Zhu P, Zhang J-J, Cen Y, Yang Y, Wang F, Gu K-P et al (2022) High endogenously synthesized N-3 polyunsaturated fatty acids in Fat-1 mice attenuate high-fat diet-induced insulin resistance by inhibiting NLRP3 inflammasome activation via Akt/GSK-3β/TXNIP pathway. Molecules 27(19):6384
pubmed: 36234919
pmcid: 9570616
doi: 10.3390/molecules27196384
Batiha GE-S, Al-Kuraishy HM, Al-Gareeb AI, Alruwaili M, AlRuwaili R, Albogami SM et al (2023) Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal. Inflammopharmacology 31(1):1–7
pubmed: 36418600
doi: 10.1007/s10787-022-01087-8
Al-Kuraishy HM, Al-Gareeb AI, Rauf A, Alhumaydhi FA, Kujawska M, El-Saber Batiha G (2023) Mechanistic insight and possible mechanism of seizure in Covid-19: the nuances and focal points. CNS Neurol Disord-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 22(6):875–83
Alkhayyat SS, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha GE-S et al (2022) Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflamm Res 71(10–11):1159–1167
pubmed: 35941297
pmcid: 9360649
doi: 10.1007/s00011-022-01615-w
Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18:S210–S212
pubmed: 22166438
doi: 10.1016/S1353-8020(11)70065-7
Tiwari PC, Pal R (2022) The potential role of neuroinflammation and transcription factors in Parkinson disease. Dialogues Clin Neurosci 19(1):71–80. https://doi.org/10.31887/DCNS.2017.19.1/rpal
doi: 10.31887/DCNS.2017.19.1/rpal
Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 184(5):2261–2271
pubmed: 20118279
doi: 10.4049/jimmunol.0901852
Clark LF, Kodadek T (2016) The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. ACS Chem Neurosci 7(5):520–527
pubmed: 27046268
doi: 10.1021/acschemneuro.6b00042
Orellana AMM, Vasconcelos AR, Leite JA, de Sá LL, Andreotti DZ, Munhoz CD et al (2015) Age-related neuroinflammation and changes in AKT-GSK-3β and WNT/β-CATENIN signaling in rat hippocampus. Aging (Albany NY) 7(12):1094
pubmed: 26647069
doi: 10.18632/aging.100853
Wang X, Chen L, Xu Y, Wang W, Wang Y, Zhang Z et al (2021) Gastrodin alleviates perioperative neurocognitive dysfunction of aged mice by suppressing neuroinflammation. Eur J Pharmacol 892:173734
pubmed: 33220272
doi: 10.1016/j.ejphar.2020.173734
Arab HH, Safar MM, Shahin NN (2021) Targeting ROS-dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson’s disease rat model. ACS Chem Neurosci 12(4):689–703
pubmed: 33543924
doi: 10.1021/acschemneuro.0c00722
Lee S, Hong DG, Yang S, Kim J, Baek M, Kim S et al (2022) Anti-inflammatory effect of IKK-activated GSK-3β inhibitory peptide prevented nigrostriatal neurodegeneration in the rodent model of Parkinson’s disease. Int J Mol Sci 23(2):998
pubmed: 35055183
pmcid: 8779943
doi: 10.3390/ijms23020998
Gao L, Zhang Y, Sterling K, Song W (2022) Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Transl Neurodegener 11(1):1–34
doi: 10.1186/s40035-022-00279-0
Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M et al (2023) The probable role of tissue plasminogen activator/neuroserpin axis in Alzheimer’s disease: a new perspective. Acta Neurol Belg 1–12. https://doi.org/10.1007/s13760-023-02403-x
Alnaaim SA, Al-kuraishy HM, Al-Gareeb AI, Ali NH, Alexiou A, Papadakis M et al (2023) New insights on the potential anti-epileptic effect of metformin: mechanistic pathway. J Cell Mol Med 27(24):3953–3965. https://doi.org/10.1111/jcmm.17965
doi: 10.1111/jcmm.17965
pubmed: 37737447
pmcid: 10747420
Ali NH, Al‐Kuraishy HM, Al‐Gareeb AI, Albuhadily AK, Hamad RS, Alexiou A et al (2023) Role of brain renin–angiotensin system in depression: a new perspective. CNS Neurosci Ther. https://doi.org/10.1111/cns.14525
Rahmani F, Saghazadeh A, Rahmani M, Teixeira AL, Rezaei N, Aghamollaii V et al (2019) Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis. Brain Res 1704:127–136
pubmed: 30296429
doi: 10.1016/j.brainres.2018.10.006
Chang E, Wang J (2021) Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson’s disease. Brain Behav 11(8):e2251
pubmed: 34132500
pmcid: 8413743
doi: 10.1002/brb3.2251
Ricci V, Pomponi M, Martinotti G, Bentivoglio A, Loria G, Bernardini S et al (2010) Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients. J Clin Psychopharmacol 30(6):751–753
pubmed: 21057246
doi: 10.1097/JCP.0b013e3181fc2ec7
Li X-T, Liang Z, Wang T-T, Yang J-W, Ma W, Deng S-K et al (2017) Brain-derived neurotrophic factor promotes growth of neurons and neural stem cells possibly by triggering the phosphoinositide 3-kinase/AKT/glycogen synthase kinase-3β/β-catenin pathway. CNS Neurol Disord-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 16(7):828–36
Xia Y, Wang CZ, Liu J, Anastasio NC, Johnson KM (2010) Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways. Neuropharmacology 58(2):330–336
pubmed: 19887077
doi: 10.1016/j.neuropharm.2009.10.009
Wada A (2009) Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3β, β-catenin, and neurotrophin cascades. J Pharmacol Sci 110(1):14–28
pubmed: 19423950
doi: 10.1254/jphs.09R02CR
Ullah A, Ali N, Ahmad S, Rahman S, Alghamdi S, Bannunah A et al (2021) Glycogen synthase kinase-3 (GSK-3) a magic enzyme: it’s role in diabetes mellitus and glucose homeostasis, interactions with fluroquionlones. A mini-review, Braz J Biol, p 83
Arciniegas Ruiz SM, Eldar-Finkelman H (2022) Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward. Front Mol Neurosci 14:792364
pubmed: 35126052
pmcid: 8813766
doi: 10.3389/fnmol.2021.792364
Martínez-González L, Gonzalo-Consuegra C, Gómez-Almería M, Porras G, de Lago E, Martín-Requero Á et al (2021) Tideglusib, a non-ATP competitive inhibitor of GSK-3β as a drug candidate for the treatment of amyotrophic lateral sclerosis. Int J Mol Sci 22(16):8975
pubmed: 34445680
pmcid: 8396476
doi: 10.3390/ijms22168975
Bhat RV, Andersson U, Andersson S, Knerr L, Bauer U, Sundgren-Andersson AK (2018) The conundrum of GSK3 inhibitors: is it the dawn of a new beginning? J Alzheimers Dis 64(s1):S547–S554
pubmed: 29758944
doi: 10.3233/JAD-179934
Pandey MK, DeGrado TR (2016) Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics 6(4):571
pubmed: 26941849
pmcid: 4775866
doi: 10.7150/thno.14334
Bastide MF, Bido S, Duteil N, Bézard E (2016) Striatal NELF-mediated RNA polymerase II stalling controls l-dopa induced dyskinesia. Neurobiol Dis 85:93–98
pubmed: 26480869
doi: 10.1016/j.nbd.2015.10.013
Kumar A, Srivastava G, Negi AS, Sharma A (2019) Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β. J Biomol Struct Dyn 37(2):275–290
pubmed: 29310523
doi: 10.1080/07391102.2018.1426043
Wei J, Wang J, Zhang J, Yang J, Wang G, Wang Y (2022) Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: strategies to improve selectivity. Eur J Med Chem 236:114301
pubmed: 35390715
doi: 10.1016/j.ejmech.2022.114301
Yao M, Teng H, Lv Q, Gao H, Guo T, Lin Y et al (2021) Anti-hyperglycemic effects of dihydromyricetin in streptozotocin-induced diabetic rats. Food Sci Human Wellness 10(2):155–162
doi: 10.1016/j.fshw.2021.02.004
Snitow ME, Bhansali RS, Klein PS (2021) Lithium and therapeutic targeting of GSK-3. Cells 10(2):255
pubmed: 33525562
pmcid: 7910927
doi: 10.3390/cells10020255
Shri SR, Manandhar S, Nayak Y, Pai KSR (2023) Role of GSK-3β inhibitors: new promises and opportunities for Alzheimer’s disease. Adv Pharm Bull 13(4):688
pubmed: 38022801
pmcid: 10676556
doi: 10.34172/apb.2023.071
Mumtaz I, Ayaz MO, Khan MS, Manzoor U, Ganayee MA, Bhat AQ et al (2022) Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease. Front Aging Neurosci 14:977411
pubmed: 36158539
pmcid: 9490081
doi: 10.3389/fnagi.2022.977411
Eldar-Finkelman H, Martinez A (2011) GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 4:32
pubmed: 22065134
pmcid: 3204427
doi: 10.3389/fnmol.2011.00032
Jeffers A, Qin W, Owens S, Koenig KB, Komatsu S, Giles FJ et al (2019) Glycogen synthase kinase-3β inhibition with 9-ING-41 attenuates the progression of pulmonary fibrosis. Sci Rep 9(1):18925
pubmed: 31831767
pmcid: 6908609
doi: 10.1038/s41598-019-55176-w
Nam G-H, Jo K-J, Park Y-S, Kawk HW, Yoo J-G, Jang JD et al (2019) Bacillus/Trapa japonica Fruit Extract Ferment Filtrate enhances human hair follicle dermal papilla cell proliferation via the Akt/ERK/GSK-3β signaling pathway. BMC Complement Altern Med 19(1):1–11
doi: 10.1186/s12906-019-2514-8
Wu Q, Ma J, Wei J, Meng W, Wang Y, Shi M (2021) lncRNA SNHG11 promotes gastric cancer progression by activating the Wnt/β-catenin pathway and oncogenic autophagy. Mol Ther 29(3):1258–1278
pubmed: 33068778
doi: 10.1016/j.ymthe.2020.10.011
Li R, Liu Z, Wu X, Yu Z, Zhao S, Tang X (2019) Lithium chloride promoted hematoma resolution after intracerebral hemorrhage through GSK-3β-mediated pathways-dependent microglia phagocytosis and M2-phenotype differentiation, angiogenesis and neurogenesis in a rat model. Brain Res Bull 152:117–127
pubmed: 31325596
doi: 10.1016/j.brainresbull.2019.07.019
Parkin GM, Thomas EA (2022) Provider perspectives on the current use of lithium medications and lithium monitoring practices for psychiatric conditions. Neuropsychiatr Dis Treat 2083–93
Ataallah B, Al-Zakhari R, Sharma A, Tofano M, Haggerty G (2020) A rare but reversible cause of lithium-induced bradycardia. Cureus 12(6):e8600. https://doi.org/10.7759/cureus.8600
doi: 10.7759/cureus.8600
pubmed: 32676239
pmcid: 7362593
Czarnywojtek A, Zgorzalewicz-Stachowiak M, Czarnocka B, Sawicka-Gutaj N, Gut P, Krela-Kazmierczak I et al (2020) Effect of lithium carbonate on the function of the thyroid gland: mechanism of action and clinical implications. J Physiol Pharmacol 71(2). https://doi.org/10.26402/jpp.2020.2.03
Shalaby HN, Zaki HF, Ain-Shoka AAA, Mohammed RA (2022) Adenosine A2A receptor blockade ameliorates mania like symptoms in rats: signaling to PKC-α and Akt/GSK-3β/β-catenin. Mol Neurobiol 59(10):6397–6410
pubmed: 35943710
pmcid: 9463338
doi: 10.1007/s12035-022-02977-2
Engel T, Goñi-Oliver P, Lucas JJ, Avila J, Hernández F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99(6):1445–1455
pubmed: 17059563
doi: 10.1111/j.1471-4159.2006.04139.x
Lazzara CA, Kim Y-H (2015) Potential application of lithium in Parkinson’s and other neurodegenerative diseases. Front Neurosci 9:403
pubmed: 26578864
pmcid: 4621308
doi: 10.3389/fnins.2015.00403
Guttuso T Jr, Shepherd R, Frick L, Feltri ML, Frerichs V, Ramanathan M et al (2023) Lithium’s effects on therapeutic targets and MRI biomarkers in Parkinson’s disease: a pilot clinical trial. IBRO Neurosci Rep 14:429–434
pubmed: 37215748
pmcid: 10196787
doi: 10.1016/j.ibneur.2023.05.001
Yang H, George SJ, Thompson DA, Silverman HA, Tsaava T, Tynan A et al (2022) Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm. Mol Med 28(1):1–13
doi: 10.1186/s10020-022-00483-8
Angeli A, Pinteala M, Maier SS, Del Prete S, Capasso C, Simionescu BC et al (2019) Inhibition of α-, β-, γ-, δ-, ζ- and η-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine. J Enzyme Inhib Med Chem 34(1):644–650
pubmed: 30727781
pmcid: 6366436
doi: 10.1080/14756366.2019.1571273
Unal G, Dokumaci AH, Ozkartal CS, Yerer MB, Aricioglu F (2019) Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3β/β-catenin signaling pathway in the SH-SY5Y cell line. Chem Biol Interact 314:108823
pubmed: 31563592
doi: 10.1016/j.cbi.2019.108823
Unal G, Aricioglu F (2020) Famotidine improved schizophrenia-like behaviors in acute ketamine model of schizophrenia in rats. Psychiatry Behav Sci 10(2):45
doi: 10.5455/PBS.20200330095749
Molinari S, Kaminski R, Di Rocco A, Yahr M (1995) The use of famotidine in the treatment of Parkinson’s disease: a pilot study. J Neural Transm-Parkinson’s Dis Dement Sect 9:243–247
doi: 10.1007/BF02259665
Huot P, Fox SH (2011) Nondopaminergic treatments for Parkinson’s disease. Neurodegener Dis Manag 1(6):491–512
doi: 10.2217/nmt.11.62
Mestre TA, Shah BB, Connolly BS, de Aquino C, Al Dhakeel A, Walsh R et al (2014) Famotidine, a histamine H2 receptor antagonist, does not reduce levodopa-induced dyskinesia in Parkinson’s disease: a proof-of-concept study. Mov Disord Clin Pract 1(3):219–224
pubmed: 30363717
pmcid: 6182979
doi: 10.1002/mdc3.12061
Ríos ALM, Gutierrez-Suarez K, Carmona Z, Ramos CG, Oliveira LFS (2022) Pharmaceuticals as emerging pollutants: case naproxen an overview. Chemosphere 291:132822
doi: 10.1016/j.chemosphere.2021.132822
Motawi TM, Bustanji Y, EL-Maraghy SA, Taha MO, Al Ghussein MA (2013) Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol 27(9):425–36
pubmed: 23784744
doi: 10.1002/jbt.21503
Motawi TM, Bustanji Y, El-Maraghy S, Taha MO, Al-Ghussein MA (2014) Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, p53 and gene expression of survivin and caspase-3. J Enzyme Inhib Med Chem 29(2):153–161
pubmed: 23368763
doi: 10.3109/14756366.2012.762645
Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW (2011) Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev Res 4(1):161–171
doi: 10.1158/1940-6207.CAPR-10-0021
Singh A, Tripathi P, Singh S (2021) Neuroinflammatory responses in Parkinson’s disease: relevance of Ibuprofen in therapeutics. Inflammopharmacology 29:5–14
pubmed: 33052479
doi: 10.1007/s10787-020-00764-w
Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Nadwa EH, Albogami SM et al (2022) Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: a hidden treasure. J Diabetes 14(12):806–814. https://doi.org/10.1111/1753-0407
doi: 10.1111/1753-0407
pubmed: 36444166
pmcid: 9789395
Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Ashour NA, Jabir MS, Negm WA et al (2023) Metformin role in Parkinson’s disease: a double-sword effect. Mol Cell Biochem 1–17. https://doi.org/10.1007/s11010-023-04771-7
Agostini F, Masato A, Bubacco L, Bisaglia M (2021) Metformin repurposing for Parkinson disease therapy: opportunities and challenges. Int J Mol Sci 23(1):398
pubmed: 35008822
pmcid: 8745385
doi: 10.3390/ijms23010398
Luo Z, Zhu T, Luo W, Lv Y, Zhang L, Wang C et al (2019) Metformin induces apoptotic cytotoxicity depending on AMPK/PKA/GSK-3β-mediated c-FLIPL degradation in non-small cell lung cancer. Cancer Manag Res 11:681–689. https://doi.org/10.2147/CMAR.S178688
doi: 10.2147/CMAR.S178688
pubmed: 30666163
pmcid: 6331071
Cao F, Yang K, Qiu S, Li J, Jiang W, Tao L et al (2023) Metformin reverses oxidative stress-induced mitochondrial dysfunction in pre-osteoblasts via the EGFR/GSK-3β/calcium pathway. Int J Mol Med 51(4):1–13
doi: 10.3892/ijmm.2023.5239
Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Nadwa EH, Albogami SM et al (2022) Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: a hidden treasure. J Diabetes 14(12):806–814
pubmed: 36444166
pmcid: 9789395
doi: 10.1111/1753-0407.13334
Su J, Zhang J, Bao R, Xia C, Zhang Y, Zhu Z et al (2021) Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3β/PP2A pathway in Parkinson’s disease. Eur J Pharmacol 907:174202
pubmed: 34048739
doi: 10.1016/j.ejphar.2021.174202
Ren Z-X, Zhao Y-F, Cao T, Zhen X-C (2016) Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson’s disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacol Sin 37(10):1315–1324
pubmed: 27374489
pmcid: 5057232
doi: 10.1038/aps.2016.42
Morales-García JA, Susín C, Alonso-Gil S, Pérez DI, Palomo V, Pérez C et al (2013) Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci 4(2):350–360
pubmed: 23421686
doi: 10.1021/cn300182g
Armagan G, Sevgili E, Gürkan FT, Köse FA, Bilgiç T, Dagcı T et al (2019) Regulation of the Nrf2 pathway by glycogen synthase kinase-3β in MPP
pubmed: 30965670
pmcid: 6480928
doi: 10.3390/molecules24071377
Yuskaitis CJ, Jope RS (2009) Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 21(2):264–273
pubmed: 19007880
doi: 10.1016/j.cellsig.2008.10.014
Del Ser T, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M et al (2013) Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 33(1):205–215
pubmed: 22936007
Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T et al (2014) Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 29(4):479–487
pubmed: 24488721
doi: 10.1002/mds.25815
Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV et al (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29(4):470–478
pubmed: 24532007
doi: 10.1002/mds.25824
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz H-J et al (2015) A phase II trial of tideglusib in Alzheimer’s disease. J Alzheimers Dis 45(1):75–88
pubmed: 25537011
doi: 10.3233/JAD-141959
Anagnostou E, Bennett TA, Thorpe K, Nicolson R (2018) A phase 2 randomized, placebo-controlled trial of tideglusib, an orally administered GSK-3 beta inhibitor, in the treatment of adolescents with ASD. 65th Annual Meeting AACAP
Horrigan J, McMorn A, Snape M, Nikolenko N, Gomes T, Lochmuller H (2018) AMO-02 (tideglusib) for the treatment of congenital and childhood onset myotonic dystrophy type 1. Neuromuscul Disord 28:S14
doi: 10.1016/S0960-8966(18)30330-4
Lazzara CA, Riley RR, Rane A, Andersen JK, Kim Y-H (2015) The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinson’s disease therapy. Brain Res 1622:127–136
pubmed: 26119916
pmcid: 4562891
doi: 10.1016/j.brainres.2015.06.018
Marras C, Herrmann N, Fischer HD, Fung K, Gruneir A, Rochon PA et al (2016) Lithium use in older adults is associated with increased prescribing of parkinson medications. Am J Geriatr Psychiatry 24(4):301–309
pubmed: 27037047
doi: 10.1016/j.jagp.2015.11.004
Zhang J, Anshul F, Malhotra DK, Jaume J, Dworkin LD, Gong R (2021) Microdose lithium protects against pancreatic islet destruction and renal impairment in streptozotocin-elicited diabetes. Antioxidants 10(1):138
pubmed: 33478120
pmcid: 7835906
doi: 10.3390/antiox10010138